Novartis Jun 11, 2026 Muscular dystrophy siRNA from Novartis' buyout of Avidity meets biomarker endpoints - FirstWord Pharma
Novartis Jun 11, 2026 Novartis RNA drug acquired in $12B Avidity deal notches a trial win - BioPharma Dive
Novartis Jun 11, 2026 Novartis $12bn bet on Avidity well placed after mid-stage FSHD win - Clinical Trials Arena
Novartis Jun 10, 2026 Novartis sticks 2nd deal with molecular glue biotech Orionis, this one worth up to $1.4B - Fierce Biotech
Novartis Jun 2, 2026 ASCO26: Celcuity's drug halves risk of disease progression, death versus Novartis' Piqray in PIK3CA-mutant breast cancer - FirstWord Pharma
Novartis May 31, 2026 Experimental Novartis radiopharma drug shows promise in early study - The Mighty 790 KFGO
Novartis May 28, 2026 Novartis ‘always looking’ for further ways to shuttle drugs to brain despite run of recent deals - Fierce Biotech
Novartis May 21, 2026 BMS eyes new campus in Texas; Novartis looks to evict tenant at Slovenian campus - Endpoints News
Novartis May 18, 2026 Novartis terminates plant contract with Chinese CDMO Porton, threatens $64M in legal claims - Fierce Pharma
Novartis May 15, 2026 Novartis, amid reorg, cuts ‘select number’ of biomedical research roles - Fierce Biotech